| 前收市價 | 9.25 |
| 開市 | 9.23 |
| 買盤 | 9.42 x 1000 |
| 賣出價 | 9.87 x 1000 |
| 今日波幅 | 9.18 - 9.93 |
| 52 週波幅 | 4.11 - 10.80 |
| 成交量 | |
| 平均成交量 | 1,179,052 |
| 市值 | 597.205M |
| Beta 值 (5 年，每月) | 0.89 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.97 |
| 業績公佈日 | 2023年2月22日 - 2023年2月27日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 13.45 |
- Benzinga
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
SVB Leerink downgraded Zymeworks Inc (NASDAQ: ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of zanidatamab to Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and the unveiling of the company's early stage pipeline. While the JAZZ/ZYME deal is robust and front-loaded, providing the company with significant free cash flow to fund operations. But based on discussions with JAZZ management, it appears unlikely that the company will opt to pursue some of the
- Benzinga
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) will acquire development and commercialization rights to Zymeworks Inc's (NASDAQ: ZYME) zanidatamab across all indications in the U.S., Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene Ltd (NASDAQ: BGNE). Zanidatamab, a HER2-targeted bispecific, is currently in pivotal trials as a second-line treatment for HER2-expressing biliary tract cancer (BTC) and first-line treatment for
- Benzinga
Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors
Zymeworks Inc (NASDAQ: ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors. The data were presented at the European Society for Medical Oncology Annual Congress. A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy. Also R
